Systematic review of mutations in pyrazinamidase associated with pyrazinamide resistance in mycobacterium tuberculosis clinical isolates

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 9, 2015, Pages 5267-5277

  Ramirez Busby, Sarah M ^a   Valafar, Faramarz ^a  

^a SAN DIEGO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDASE; PYRAZINAMIDASE; PYRAZINAMIDE; UNCLASSIFIED DRUG; PYRAZINAMIDE DEAMIDASE; TUBERCULOSTATIC AGENT;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL STRAIN; BACTERIUM ISOLATE; CODON; GENE MUTATION; HUMAN; MICROBIAL DIVERSITY; MINIMUM INHIBITORY CONCENTRATION; MUTATION RATE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; DRUG EFFECTS; ENZYMOLOGY; GENETICS; METABOLISM; MICROBIAL SENSITIVITY TEST; MUTATION;

AMIDOHYDROLASES; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE;

EID: 84940931132     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00204-15     Document Type: Review

References (110)

1. World Health Organization. 2014. Global tuberculosis report 2014. World Health Organization, Geneva, Switzerland.
2. Zhang Y, Mitchison D. 2003. The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis 7:6-21.
3. Heifets L, Lindholm-Levy P. 1992. Pyrazinamide sterilizing activity in vitro against semidormant Mycobacterium tuberculosis bacterial populations. Am Rev Respir Dis 145:1223-1225. http://dx.doi.org/10.1164/ajrccm/145.5.1223.
4. Steele MA, Des Prez RM. 1988. The role of pyrazinamide in tuberculosis chemotherapy. Chest 94:845-850. http://dx.doi.org/10.1378/chest.94.4 .845.
5. Konno K, Feldmann FM, McDermott W. 1967. Pyrazinamide susceptibility and amidase activity of tubercle bacilli. Am Rev Respir Dis 95: 461-469.
6. Hu Y, Coates AR, Mitchison DA. 2006. Sterilising action of pyrazinamide in models of dormant and rifampicin-tolerant Mycobacterium tuberculosis. Int J Tuberc Lung Dis 10:317-322.
7. Mitchison DA. 1985. The action of antituberculosis drugs in shortcourse chemotherapy. Tubercle 66:219-225. http://dx.doi.org/10.1016/0041-3879(85)90040-6.
8. Hoffner S, Angeby K, Sturegard E, Jönsson B, Johansson A, Sellin M, Werngren J. 2013. Proficiency of drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide: the Swedish experience. Int J Tuberc Lung Dis 17:1486-1490. http://dx.doi.org/10.5588/ijtld.13.0195.
9. Chang KC, Yew WW, Zhang Y. 2011. Pyrazinamide susceptibility testing in Mycobacterium tuberculosis: a systematic review with metaanalyses. Antimicrob Agents Chemother 55:4499-4505. http://dx.doi.org/10.1128/AAC.00630-11.
10. Zhang Y, Permar S, Sun Z. 2002. Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J Med Microbiol 51:42-49.
11. Salfinger M, Heifets LB. 1988. Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method. Antimicrob Agents Chemother 32:1002-1004. http://dx.doi.org/10.1128/AAC.32.7.1002.
12. Cunha J. 2012. Pyrazinamide susceptibility testing in all isolates of the Mycobacterium tuberculosis complex-a critical analysis. Rev Port Pneumol 18:188-189. http://dx.doi.org/10.1016/j.rppneu.2011.12.002.
13. Zimic M, Fuentes P, Gilman R. 2012. Pyrazinoic acid efflux rate in Mycobacterium tuberculosis is a better proxy of pyrazinamide resistance. Tuberculosis 92:84-91. http://dx.doi.org/10.1016/j.tube.2011.09.002.
14. World Health Organization. 2009. Guidelines for surveillance of drug resistance in tuberculosis, 4th ed. WHO/HTM/TB/2009.422. World Health Organization, Geneva, Switzerland.
15. Campbell PJ, Morlock GP, Sikes RD, Dalton TL, Metchock B, Starks AM, Hooks DP, Cowan LS, Plikaytis BB, Posey JE. 2011. Molecular detection of mutations associated with first-and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob Agents Chemother 55:2032-2041. http://dx.doi.org/10.1128/AAC.01550-10.
16. Denkin S, Volokhov D, Chizhikov V, Zhang Y. 2005. Microarray-based pncA genotyping of pyrazinamide-resistant strains of Mycobacterium tuberculosis. J Med Microbiol 54:1127-1131. http://dx.doi.org/10.1099/jmm.0.46129-0.
17. Sekiguchi J-I, Nakamura T, Miyoshi-Akiyama T, Kirikae F, Kobayashi I, Augustynowicz-Kopec E, Zwolska Z, Morita K, Suetake T, Yoshida H, Kato S, Mori T, Kirikae T. 2007. Development and evaluation of a line probe assay for rapid identification of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis strains. J Clin Microbiol 45: 2802-2807. http://dx.doi.org/10.1128/JCM.00352-07.
18. Wayne LG. 1974. Simple pyrazinamidase and urease tests for routine identification of mycobacteria. Am Rev Respir Dis 109:147-151.
19. Kalokhe AS, Shafiq M, Lee JC, Ray SM, Wang YF, Metchock B, Anderson AM, Nguyen MLT. 2013. Multidrug-resistant tuberculosis drug susceptibility and molecular diagnostic testing. Am J Med Sci 345: 143-148. http://dx.doi.org/10.1097/MAJ.0b013e31825d32c6.
20. Rodwell TC, Valafar F, Douglas J, Qian L, Garfein RS, Chawla A, Torres J, Zadorozhny V, Soo Kim M, Hoshide M, Catanzaro D, Jackson L, Lin G, Desmond E, Rodrigues C, Eisenach K, Victor TC, Ismail N, Crudu V, Gle MT, Catanzaro A. 2014. Predicting extensively drug-resistant tuberculosis (XDR-TB) phenotypes with genetic mutations. J Clin Microbiol 52:781-789. http://dx.doi.org/10.1128/JCM.02701-13.
21. Scorpio A, Zhang Y. 1996. Mutations in pncA, a gene encoding pyrazinamidase/ nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat Med 2:662-667. http://dx.doi.org/10.1038/nm0696-662.
22. Li J, Ji L, Shi W, Xie J, Zhang Y. 2013. Trans-translation mediates tolerance to multiple antibiotics and stresses in Escherichia coli. J Antimicrob Chemother 68:2477-2481. http://dx.doi.org/10.1093/jac/dkt231.
23. Zhang S, Chen J, Shi W, Liu W, Zhang W, Zhang Y. 2013. Mutations in panD encoding aspartate decarboxylase are associated with pyrazinamide resistance in Mycobacterium tuberculosis. Emerg Microbes Infect 2:e34. http://dx.doi.org/10.1038/emi.2013.38.
24. Zimhony O, Cox JS, Welch JT, Vilchèze C, Jacobs WR. 2000. Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis. Nat Med 6:1043-1047. http://dx.doi.org/10.1038/79558.
25. Alexander DC, Ma JH, Guthrie JL, Blair J, Chedore P, Jamieson FB. 2012. Gene sequencing for routine verification of pyrazinamide resistance in Mycobacterium tuberculosis: a role for pncA but not rpsA. J Clin Microbiol 50:3726-3728. http://dx.doi.org/10.1128/JCM.00620-12.
26. Dillon NA, Peterson ND, Rosen BC, Baughn AD. 2014. Pantothenate and pantetheine antagonize the anti-tubercular activity of pyrazinamide. Antimicrob Agents Chemother 58:7258-7263. http://dx .doi.org/10.1128/AAC.04028-14.
27. Boshoff H, Mizrahi V, Barry C. 2002. Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I. J Bacteriol 184:2167-2172. http://dx.doi.org/10.1128/JB.184.8 .2167-2172.2002.
28. Shi W, Zhang X, Jiang X, Yuan H, Lee J. 2011. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science 333:1630-1632. http://dx.doi.org/10.1126/science.1208813.
29. Doustdar F, Khosravi AD, Farnia P. 2009. Mycobacterium tuberculosis genotypic diversity in pyrazinamide-resistant isolates of Iran. Microb Drug Resist 15:251-256. http://dx.doi.org/10.1089/mdr.2009.0066.
30. Jnawali HN, Hwang SC, Park YK, Kim H, Lee YS, Chung GT, Choe KH, Ryoo S. 2013. Characterization of mutations in multi-and exten-sive drug resistance among strains of Mycobacterium tuberculosis clinical isolates in Republic of Korea. Diagn Microbiol Infect Dis 76:187-196. http://dx.doi.org/10.1016/j.diagmicrobio.2013.02.035.
31. Jonmalung J, Prammananan T, Leechawengwongs M, Chaiprasert A. 2010. Surveillance of pyrazinamide susceptibility among multidrugresistant Mycobacterium tuberculosis isolates from Siriraj Hospital, Thailand. BMC Microbiol 10:223. http://dx.doi.org/10.1186/1471-2180-10-223.
32. Sachais B, Nachamkin I, Mills J, Leonard D. 1998. Novel pncA mutations in pyrazinamide-resistant isolates of Mycobacterium tuberculosis. Mol Diagn 3:229-231. http://dx.doi.org/10.1016/S1084-8592 (98)80045-3.
33. Wade MM, Volokhov D, Peredelchuk M, Chizhikov V, Zhang Y. 2004. Accurate mapping of mutations of pyrazinamide-resistant Mycobacterium tuberculosis strains with a scanning-frame oligonucleotide microarray. Diagn Microbiol Infect Dis 49:89-97. http://dx.doi.org/10.1016/j.diagmicrobio.2004.01.001.
34. Huang T, Lee S, Tu H. 2003. Correlation between pyrazinamide activity and pncA mutations in Mycobacterium tuberculosis isolates in Taiwan. Antimicrob Agents Chemother 47:3672-3673. http://dx.doi.org/10.1128/AAC.47.11.3672-3673.2003.
35. Ando H, Mitarai S, Kondo Y, Suetake T, Sekiguchi J-I, Kato S, Mori T, Kirikae T. 2010. Pyrazinamide resistance in multidrug-resistant Mycobacterium tuberculosis isolates in Japan. Clin Microbiol Infect 16:1164-1168. http://dx.doi.org/10.1111/j.1469-0691.2009.03078.x.
36. Aragón LM, Garrigó M, Moreno C, Español M, Coll P. 2007. Evaluation of the BacT/Alert PZA kit in comparison with the Bactec 460TB PZA for testing Mycobacterium tuberculosis susceptibility to pyrazinamide. J Antimicrob Chemother 60:655-657. http://dx.doi.org/10.1093/jac/dkm252.
37. Barco P, Cardoso RF, Hirata RDC, Leite CQF, Pandolfi JR, Sato DN, Shikama ML, de Melo FF, Mamizuka EM, Campanerut PA, Hirata ZMH. 2006. pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis clinical isolates from the southeast region of Brazil. J Antimicrob Chemother 58:930-935. http://dx.doi.org/10.1093/jac/dkl363.
38. Bishop KS, Blumberg L, Trollip AP, Smith A, Roux NL, York DF, Kiepiela P. 2001. Characterisation of the pncA gene in Mycobacterium tuberculosis isolates from Gauteng, South Africa. Int J Tuberc Lung Dis 5:952-957.
39. Brown T, Tansel Ö , French G. 2000. Simultaneous identification and typing of multi-drug-resistant Mycobacterium tuberculosis isolates by analysis of pncA and rpoB. J Med Microbiol 49:651-656.
40. Cheng SJ, Thibert L, Sanchez T, Heifets L, Zhang Y. 2000. pncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: spread of a monoresistant strain in Quebec, Canada. Antimicrob Agents Chemother 44:528-532. http://dx.doi.org/10.1128/AAC.44.3.528-532.2000.
41. Chiu Y-C, Huang S-F, Yu K-W, Lee Y-C, Feng J-Y, Su W-J. 2011. Characteristics of pncA mutations in multidrug-resistant tuberculosis in Taiwan. BMC Infect Dis 11:240. http://dx.doi.org/10.1186/1471-2334-11-240.
42. Clemente WT, Soares Lima SS, Palaci M, Silva MSN, Sumnienski Rodrigues VF, Dalla Costa ER, Possuelo L, Cafrune PI, Ribeiro FK, Gomes HM, Serufo JC. 2008. Phenotypic and genotypic characterization of drug-resistant Mycobacterium tuberculosis strains. Microbiol Infect Dis 62:199-204. http://dx.doi.org/10.1016/j.diagmicrobio.2008.06 .013.
43. Cuevas-Córdoba B, Xochihua-González SO, Cuellar A, Fuentes-Domínguez J, Zenteno-Cuevas R. 2013. Characterization of pncA gene mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates from Mexico. Infect Genet Evol 19:330-334. http://dx.doi.org/10.1016/j.meegid.2012.12.013.
44. Daum LT, Rodriguez JD, Worthy SA, Ismail NA, Omar SV, Dreyer AW, Fourie PB, Hoosen AA, Chambers JP, Fischer GW. 2012. Nextgeneration ion torrent sequencing of drug resistance mutations in Mycobacterium tuberculosis strains. J Clin Microbiol 50:3831-3837. http://dx.doi.org/10.1128/JCM.01893-12.
45. Davies AP, Billington OJ, McHugh TD, Mitchison DA, Gillespie SH. 2000. Comparison of phenotypic and genotypic methods for pyrazinamide susceptibility testing with Mycobacterium tuberculosis. J Clin Microbiol 38:3686-3688.
46. Endoh T, Yagihashi A, Uehara N, Kobayashi D, Tsuji N, Nakamura M, Hayashi S, Fujii N, Watanabe N. 2002. Pyrazinamide resistance associated with pncA gene mutation in Mycobacterium tuberculosis in Japan. Epidemiol Infect 128:337-342.
47. Feuerriegel S, Oberhauser B, George AG, Dafae F, Richter E, Rüsch-Gerdes S, Niemann S. 2012. Sequence analysis for detection of first-line drug resistance in Mycobacterium tuberculosis strains from a highincidence setting. BMC Microbiol 12:90. http://dx.doi.org/10.1186/1471-2180-12-90.
48. Hannan MM, Desmond EP, Morlock GP, Mazurek GH, Crawford JT. 2001. Pyrazinamide-monoresistant Mycobacterium tuberculosis in the United States. J Clin Microbiol 39:647-650. http://dx.doi.org/10.1128/JCM.39.2.647-650.2001.
49. Hirano K, Takahashi M, Kazumi Y, Fukasawa Y, Abe C. 1997. Mutation in pncA is a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis. Tuber Lung Dis 78:117-122.
50. Hou L, Osei-Hyiaman D, Zhang Z, Wang B, Yang A, Kano K. 2000. Molecular characterization of pncA gene mutations in Mycobacterium tuberculosis clinical isolates from China. Epidemiol Infect 124:227-232. http://dx.doi.org/10.1017/S0950268899003635.
51. Juréen P, Werngren J, Toro J-C, Hoffner S. 2008. Pyrazinamide resistance and pncA gene mutations in Mycobacterium tuberculosis. Antimicrob Agents Chemother 52:1852-1854. http://dx.doi.org/10.1128/AAC .00110-08.
52. Lee A, Tang L, Lim I, Wong SY. 2002. Characterization of pyrazinamide and ofloxacin resistance among drug-resistant Mycobacterium tuberculosis isolates from Singapore. Int J Infect Dis 6:48-51. http://dx.doi.org/10.1016/S1201-9712(02)90136-0.
53. Lemaitre N, Sougakoff W, Truffot-Pernot C, Jarlier V. 1999. Characterization of new mutations in pyrazinamide-resistant strains of Mycobacterium tuberculosis and identification of conserved regions important for the catalytic activity of the pyrazinamidase PncA. Antimicrob Agents Chemother 43:1761-1763.
54. Marttila HJ, Marjamäki M, Vyshnevskaya E, Vyshnevskiy BI, Otten TF, Vasilyef A, Viljanen VMK. 1999. pncA mutations in pyrazinamideresistant Mycobacterium tuberculosis isolates from northwestern Russia. Antimicrob Agents Chemother 43:1764-1766.
55. McCammon MT, Gillette JS, Thomas DP, Ramaswamy SV, Rosas II, Graviss EA, Vijg J, Quitugua TN. 2005. Detection by denaturing gradient gel electrophoresis of pncA mutations associated with pyrazinamide resistance in Mycobacterium tuberculosis isolates from the United States-Mexico border region. Antimicrob Agents Chemother 49:2210-2217. http://dx.doi.org/10.1128/AAC.49.6.2210-2217.2005.
56. Mestdagh M, Fonteyne PA, Realini L, Rossau R, Jannes G, Mijs W, De Smet KA, Portaels F, Van den Eeckhout E. 1999. Relationship between pyrazinamide resistance, loss of pyrazinamidase activity, and mutations in the pncA locus in multidrug-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 43:2317-2319.
57. Miyagi C, Yamane N, Yogesh B, Ano H, Takashima T. 2004. Genetic and phenotypic characterization of pyrazinamide-resistant Mycobacterium tuberculosis complex isolates in Japan. Diagn Microbiol Infect Dis 48:111-116. http://dx.doi.org/10.1016/j.diagmicrobio.2003.09.013.
58. Morlock GP, Crawford JT, Butler WR, Brim SE, Sikes D, Mazurek GH, Woodley CL, Cooksey RC. 2000. Phenotypic characterization of pncA mutants of Mycobacterium tuberculosis. Antimicrob Agents Chemother 44:2291-2295. http://dx.doi.org/10.1128/AAC.44.9.2291-2295 .2000.
59. Mphahlele M, Syre H, Valvatne H, Stavrum R, Mannsaker T, Muthivhi T, Weyer K, Fourie PB, Grewal HMS. 2008. Pyrazinamide resistance among South African multidrug-resistant Mycobacterium tuberculosis isolates. J Clin Microbiol 46:3459-3464. http://dx.doi.org/10.1128/JCM.00973-08.
60. Muthaiah M, Jagadeesan S, Ayalusamy N, Sreenivasan M, Prabhu SS, Muthuraj U, Senthilkumar K, Veerappan S. 2010. Molecular epidemiological study of pyrazinamide-resistance in clinical isolates of Mycobacterium tuberculosis from South India. Int J Mol Sci 11:2670-2680. http://dx.doi.org/10.3390/ijms11072670.
61. Pandey S, Newton S, Upton A. 2009. Characterisation of pncA mutations in clinical Mycobacterium tuberculosis isolates in New Zealand. Pathology 41:582-584. http://dx.doi.org/10.1080/00313020903071587.
62. Park SK, Lee JY, Chang CL, Lee MK, Son HC, Kim CM, Jang HJ, Park HK, Jeong SH. 2001. pncA mutations in clinical Mycobacterium tuberculosis isolates from Korea. BMC Infect Dis 1:4. http://dx.doi.org/10.1186/1471-2334-1-4.
63. Portugal I, Barreiro L, Moniz-Pereira J, Brum L. 2004. pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates in Portugal. Antimicrob Agents Chemother 48:2736-2738. http://dx.doi.org/10.1128/AAC.48.7.2736-2738.2004.
64. Rodrigues VDFS, Telles MA, Ribeiro MO, Cafrune PI, Rossetti MLR, Zaha A. 2005. Characterization of pncA mutations in pyrazinamideresistant Mycobacterium tuberculosis in Brazil. Antimicrob Agents Chemother 49:444-446. http://dx.doi.org/10.1128/AAC.49.1.444-446.2005.
65. Scorpio A, Lindholm-Levy P, Heifets L, Gilman R, Siddiqi SH, Cynamon M, Zhang Y. 1997. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 41:540-543.
66. Sekiguchi J, Miyoshi-Akiyama T, Augustynowicz-Kopeć E, Zwolska Z, Kirikae F, Toyota E, Kobayashi I, Morita K, Kudo K, Kato S, Kuratsuji T, Mori T, Kirikae T. 2007. Detection of multidrug resistance in Mycobacterium tuberculosis. J Clin Microbiol 45:179-192. http://dx.doi.org/10.1128/JCM.00750-06.
67. Sheen P, Ferrer P, Gilman RH, López-Llano J, Fuentes P, Valencia E, Zimic MJ. 2009. Effect of pyrazinamidase activity on pyrazinamide resistance in Mycobacterium tuberculosis. Tuberculosis (Edinb) 89:109-113. http://dx.doi.org/10.1016/j.tube.2009.01.004.
68. Sheen P, Méndez M, Gilman RH, Peña L, Caviedes L, Zimic MJ, Zhang Y, Moore DA, Evans CA. 2009. Sputum PCR-single-strand conformational polymorphism test for same-day detection of pyrazinamide resistance in tuberculosis patients. J Clin Microbiol 47:2937-2943. http://dx.doi.org/10.1128/JCM.01594-08.
69. Shenai S, Rodrigues C, Sadani M, Sukhadia N, Mehta A. 2009. Comparison of phenotypic and genotypic methods for pyrazinamide susceptibility testing. Indian J Tuberc 56:82-90.
70. Simons SO, van Ingen J, van der Laan T, Mulder A, Dekhuijzen PNR, Boeree MJ, van Soolingen D. 2012. Validation of pncA gene sequencing in combination with the mycobacterial growth indicator tube method to test susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Clin Microbiol 50:428-434. http://dx.doi.org/10.1128/JCM.05435-11.
71. Somoskovi A, Dormandy J, Parsons LM, Kaswa M, Goh KS, Rastogi N, Salfinger M. 2007. Sequencing of the pncA gene in members of the Mycobacterium tuberculosis complex has important diagnostic applications: Identification of a species-specific pncA mutation in "Mycobacterium canettii" and the reliable and rapid predictor of pyrazinamide resistance. J Clin Microbiol 45:595-599. http://dx.doi.org/10.1128/JCM .01454-06.
72. Sreevatsan S, Pan X, Zhang Y, Kreiswirth BN, Musser JM. 1997. Mutations associated with pyrazinamide resistance in pncA of Mycobacterium tuberculosis complex organisms. Antimicrob Agents Chemother 41:636-640.
73. Stoffels K, Mathys V, Fauville-Dufaux M, Wintjens R, Bifani P. 2012. Systematic analysis of pyrazinamide-resistant spontaneous mutants and clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 56:5186-5193. http://dx.doi.org/10.1128/AAC.05385-11.
74. Suzuki Y, Suzuki A, Tamaru A, Katsukawa C, Oda H. 2002. Rapid detection of pyrazinamide-resistant Mycobacterium tuberculosis by a PCR-based in vitro system. J Clin Microbiol 40:501-507. http://dx.doi.org/10.1128/JCM.40.2.501-507.2002.
75. Therese KL, Gayathri R, Balasubramanian S, Natrajan S, Madhavan HN. 2012. Phenotypic and genotypic characteristics of drug resistance in Mycobacterium tuberculosis isolates from pediatric population of Chennai, India. Indian J Med Microbiol 30:411-417. http://dx.doi.org/10.4103/0255-0857.103761.
76. Tracevska T, Jansone I, Baumanis V, Nodieva A, Marga O, Skenders G. 2004. Spectrum of pncA mutations in multidrug-resistant Mycobacterium tuberculosis isolates obtained in Latvia. Antimicrob Agents Chemother 48:3209-3210. http://dx.doi.org/10.1128/AAC.48.8.3209-3210 .2004.
77. Werngren J, Sturegard E, Juréen P, Angeby K, Hoffner S, Schön T. 2012. Reevaluation of the critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide using wildtype MIC distributions and pncA gene sequencing. Antimicrob Agents Chemother 56:1253-1257. http://dx.doi.org/10.1128/AAC.05894-11.
78. Yüksel P, Tansel O. 2009. Characterization of pncA mutations of pyrazinamide-resistant Mycobacterium tuberculosis in Turkey. New Microbiol 32:153-158.
79. Zhang H, Bi L-J, Li C-Y, Sun Z-G, Deng J-Y, Zhang X-E. 2009. Mutations found in the pncA gene of Mycobacterium tuberculosis in clinical pyrazinamide-resistant isolates from a local region of China. J Int Med Res 37: 1430-1435. http://dx.doi.org/10.1177/147323000903700517.
80. Zhou M, Geng X, Chen J, Wang X, Wang D, Deng J, Zhang Z, Wang W, Zhang X-E, Wei H. 2011. Rapid colorimetric testing for pyrazinamide susceptibility of M. tuberculosis by a PCR-based in-vitro synthesized pyrazinamidase method. PLoS One 6:e27654. http://dx.doi.org/10.1371/journal.pone.0027654.
81. Pholwat S, Stroup S, Gratz J, Trangan V, Foongladda S, Kumburu H, Juma SP, Kibiki G, Houpt E. 2014. Pyrazinamide susceptibility testing of Mycobacterium tuberculosis by high resolution melt analysis. Tuberculosis (Edinb) 94:20-25. http://dx.doi.org/10.1016/j.tube.2013.10.006.
82. Huang Z-K, Luo Q, Jiang B-X, Li W-T, Xu X-M, Xiong G-L, Li J-M. 2013. Performance of the microscopic observation drug susceptibility assay in pyrazinamide susceptibility testing for Mycobacterium tuberculosis. Chin Med J (Engl) 126:4334-4339.
83. Watcharasamphankul W, Houpt ER, Foongladda S. 2013. Rapid detection of pyrazinamide resistant Mycobacterium tuberculosis by high resolution melting curve analysis. J Med Assoc Thai 96:1218-1223.
84. Miotto P, Cabibbe AM, Feuerriegel S, Casali N, Drobniewski F, Rodionova Y, Bakonyte D, Stakenas P, Pimkina E, Augustynowicz-Kopeć E, Degano M, Ambrosi A, Hoffner S, Mansjö M, Werngren J, Rüsch-Gerdes S, Niemann S, Cirillo DM. 2014. Mycobacterium tuberculosis pyrazinamide resistance determinants: a multicenter study. mBio 5(5):e01819-14. http://dx.doi.org/10.1128/mBio.01819-14.
85. Aono A, Chikamatsu K, Yamada H, Kato T, Mitarai S. 2014. Association between pncA gene mutations, pyrazinamidase activity, and pyrazinamide susceptibility testing in Mycobacterium tuberculosis. Antimicrob Agents Chemother 58:4928-4930. http://dx.doi.org/10.1128/AAC .02394-14.
86. Georghiou SB, Magana M, Garfein RS, Catanzaro DG, Catanzaro A, Rodwell TC. 2012. Evaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic review. PLoS One 7:e33275. http://dx.doi.org/10.1371/journal.pone.0033275.
87. Rosenkrantz JT, Aarts H, Abee T, Rolfe MD, Knudsen GM, Nielsen M-B, Thomsen LE, Zwietering MH, Olsen JE, Pin C. 2013. Nonessential genes form the hubs of genome scale protein function and environmental gene expression networks in Salmonella enterica serovar Typhimurium. BMC Microbiol 13:294. http://dx.doi.org/10.1186/1471-2180-13-294.
88. Boshoff HIM, Xu X, Tahlan K, Dowd CS, Pethe K, Camacho LR, Park T-H, Yun C-S, Schnappinger D, Ehrt S, Williams KJ, Barry CE. 2008. Biosynthesis and recycling of nicotinamide cofactors in Mycobacterium tuberculosis. An essential role for NAD in nonreplicating bacilli. J Biol Chem 283:19329-19341.
89. Lawn SD, Nicol MP. 2011. Xpert MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance. Future Microbiol 6:1067-1082. http://dx.doi.org/10.2217/fmb.11.84.
90. Hewlett D, Horn DL, Alfalla C. 1995. Drug-resistant tuberculosis: inconsistent results of pyrazinamide susceptibility testing. JAMA 273: 916-917. http://dx.doi.org/10.1001/jama.1995.03520360029021.
91. Chedore P, Bertucci L, Wolfe J, Sharma M, Jamieson F. 2010. Potential for erroneous results indicating resistance when using the Bactec MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Clin Microbiol 48:300-301. http://dx.doi.org/10.1128/JCM .01775-09.
92. Mitchison D, Davies G. 2012. The chemotherapy of tuberculosis: past, present and future. Int J Tuberc Lung Dis 16:724-732. http://dx.doi.org/10.5588/ijtld.12.0083.
93. Phanouvong S, Vrakking H, Blanc L, Wondemagegnehu E, Moore T, Rago L, Mboussa J, Norval P, Matji R. 2002. Operational guide for national tuberculosis control programmes on the introduction and use of fixed-dose combination drugs. World Health Organization, Geneva, Switzerland.
94. Xiong A-S, Yao Q-H, Peng R-H, Li X, Fan H-Q, Cheng Z-M, Li Y. 2004. A simple, rapid, high-fidelity and cost-effective PCR-based twostep DNA synthesis method for long gene sequences. Nucleic Acids Res 32:e98. http://dx.doi.org/10.1093/nar/gnh094.
95. Köser CU, Bryant JM, Becq J, Török ME, Ellington MJ, Marti-Renom MA, Carmichael AJ, Parkhill J, Smith GP, Peacock SJ. 2013. Wholegenome sequencing for rapid susceptibility testing of M. tuberculosis. N Engl J Med 369:290-292. http://dx.doi.org/10.1056/NEJMc1215305.
96. Farhat MR, Shapiro BJ, Kieser KJ, Sultana R, Jacobson KR, Victor TC, Warren RM, Streicher EM, Calver A, Sloutsky A, Kaur D, Posey JE, Plikaytis B, Oggioni MR, Gardy JL, Johnston JC, Rodrigues M, Tang PKC, Kato-Maeda M, Borowsky ML, Muddukrishna B, Kreiswirth BN, Kurepina N, Galagan J, Gagneux S, Birren B, Rubin EJ, Lander ES, Sabeti PC, Murray M. 2013. Genomic analysis identifies targets of convergent positive selection in drug-resistant Mycobacterium tuberculosis. Nat Genet 45:1183-1189. http://dx.doi.org/10.1038/ng.2747.
97. Hauser PM, Bernard T, Greub G, Jaton K, Pagni M, Hafen GM. 2014. Microbiota present in cystic fibrosis lungs as revealed by whole genome sequencing. PLoS One 9:e90934. http://dx.doi.org/10.1371/journal.pone .0090934.
98. Quail MA, Smith M, Coupland P, Otto TD, Harris SR, Connor TR, Bertoni A, Swerdlow HP, Gu Y. 2012. A tale of three next generation sequencing platforms: comparison of Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers. BMC Genomics 13:341. http://dx.doi.org/10.1186/1471-2164-13-341.
99. Sreevatsan S, Pan X, Stockbauer KE, Connell ND, Kreiswirth BN, Whittam TS, Musser JM. 1997. Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indicates evolutionarily recent global dissemination. Proc Natl Acad Sci U S A 94:9869-9874. http://dx.doi.org/10.1073/pnas.94.18.9869.
100. McClatchy JK, Tsang AY, Cernich MS. 1981. Use of pyrazinamidase activity on Mycobacterium tuberculosis as a rapid method for determination of pyrazinamide susceptibility. Antimicrob Agents Chemother 20: 556-557. http://dx.doi.org/10.1128/AAC.20.4.556.
101. Trivedi S, Desai S. 1987. Pyrazinamidase activity of Mycobacterium tuberculosis-a test of sensitivity to pyrazinamide. Tubercle 68:221-224. http://dx.doi.org/10.1016/0041-3879(87)90058-4.
102. Miller MA, Thibert L, Desjardins F, Siddiqi SH, Dascal A. 1995. Testing of susceptibility of Mycobacterium tuberculosis to pyrazinamide: comparison of Bactec method with pyrazinamidase assay. J Clin Microbiol 33:2468-2470.
103. Petrella S, Gelus-Ziental N, Maudry A, Laurans C, Boudjelloul R, Sougakoff W. 2011. Crystal structure of the pyrazinamidase of Mycobacterium tuberculosis: insights into natural and acquired resistance to pyrazinamide. PLoS One 6:e15785. http://dx.doi.org/10.1371/journal.pone .0015785.
104. Huyen MNT, Kremer K, Lan NTN, Cobelens FGJ, Buu TN, Dung NH, Caws M, Tiemersma EW, van Soolingen D. 2012. Mixed tuberculosis infections in rural South Vietnam. J Clin Microbiol 50:1586-1592. http://dx.doi.org/10.1128/JCM.00434-12.
105. Havlik JA, Horsburgh CR, Metchock B, Williams PP, Fann SA, Thompson SE. 1992. Disseminated Mycobacterium avium complex infection: clinical identification and epidemiologic trends. J Infect Dis 165: 577-580. http://dx.doi.org/10.1093/infdis/165.3.577.
106. McDowell DG, Burns NA, Parkes HC. 1998. Localised sequence regions possessing high melting temperatures prevent the amplification of a DNA mimic in competitive PCR. Nucleic Acids Res 26:3340-3347. http://dx.doi.org/10.1093/nar/26.14.3340.
107. Comas I, Borrell S, Roetzer A, Rose G. 2012. Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes. Nat Genet 44:106-110.
108. de Vos M, Müller B, Borrell S, Black PA, van Helden PD, Warren RM, Gagneux S, Victor TC. 2013. Putative compensatory mutations in the rpoC gene of rifampin-resistant Mycobacterium tuberculosis are associated with ongoing transmission. Antimicrob Agents Chemother 57:827-832. http://dx.doi.org/10.1128/AAC.01541-12.
109. Centers for Disease Control and Prevention. 2011. Fact sheets: the difference between latent TB infection and TB disease. Centers for Disease Control and Prevention, Atlanta, GA.
110. Burman WJ, Gallicano K, Peloqui C. 1999. Therapeutic implications of drug interactions in the treatment of human immunodeficiency virusrelated tuberculosis. Clin Infect Dis 28:419-429, quiz 430. http://dx.doi.org/10.1086/515174.